11月3日，可申购北交所的北矿检测（920160.BJ ），另有一只新股上市，同为北交所的丹娜生物 （920009.BJ）。 一只新股申购 北矿检测源于1956年创立的原北京矿冶研究总院分析研究室，2016年成立并成为独立法人单位。公司是 国内领先的有色金属检验检测技术研发与服务机构之一，专业从事有色金属矿产资源检验检测技术研 发、技术服务及仪器研发，业务涵盖矿石及矿产品、技术推广、高端分析仪器研发等领域。 | | 今日申购 | | | | --- | --- | --- | --- | | | 920160.BJ 北矿检测 | | | | 发行价(元/股) | 机构报价(元/股) | 市值(亿元) | 所属行业 | | 6.70 | - | = | M745质检技术服 | | | | | ਲ | | 发行市盈率 | 行业市盈率 | 可比公司 | 可比公司动态市盈率 | | | | 华测检测 | 24.32 | | 14.99 | 38.77 | 钢研纳克 | 42.30 | | | | 谱尼测试 | 亏损 | | | 业绩情况 | | | | 1.6 1.4 | | | 80% 70% | 据介绍，北矿检测 ...

Core Insights - The report emphasizes the importance of high-quality financial services to support the real economy, driven by government policies aimed at enhancing financial strength and development [5][4] - The report highlights the significant growth potential in the invasive fungal disease diagnostics market, with a projected increase from 240 million yuan in 2018 to 3.03 billion yuan by 2030, representing a compound annual growth rate of 23.5% [8] - The report indicates that the photovoltaic industry is approaching a turning point, with recommendations for various companies based on their strategic directions and market positions [15][13] Industry Commentary - The non-bank financial sector is experiencing a policy-driven push for high-quality development, focusing on enhancing financial services for key areas such as technology innovation and small enterprises [4][5] - The photovoltaic industry is currently facing a supply-demand imbalance, with expectations of price stability in the short term due to reduced production and inventory pressures [12][14] - The report notes that the invasive fungal disease's incidence is rising, necessitating early diagnosis, which is increasingly facilitated by serological testing methods [8] Company Commentary - Dana Biologicals is recognized as a national-level specialized and innovative "little giant" enterprise, focusing on the development and sales of diagnostic products for invasive fungal diseases [8] - The company has shown a strong competitive advantage in the invasive fungal disease diagnostics field, supported by a robust R&D team and multiple technology platforms [8] - JuJiao Co., Ltd. reported record high performance in Q3 2025, with revenue of 545 million yuan, a year-on-year increase of 7.78%, driven by strategic sales initiatives and product upgrades [11][7]